Análisis de la app SIBIONICS GS1 para 31 de julio

Regulatory Information: The SIBIONICS GS1 Continuous Glucose Monitoring (CGM) system is a CE-marked medical device (CE Mark issued under EU MDR). This app is only intended for use with SIBIONICS GS1 CGM sensors, which are legally available in the following countries and regions only: Europe Albania, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, North Macedonia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Ireland, Iceland, France, Finland, Greece, Hungary, Italy, Kosovo, Latvia, Lithuania, Luxembourg, Malta, Montenegro, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Sweden, Switzerland, Türkiye, Ukraine, United Kingdom Asia Afghanistan, Azerbaijan, Bahrain, Brunei, Hong Kong SAR, Indonesia, Iraq, Israel, Jordan, Kazakhstan, Kuwait, Macao SAR, Malaysia, Maldives, Mongolia, Oman, Pakistan, Qatar, Saudi Arabia, Singapore, South Korea, Sri Lanka, Tajikistan, Turkmenistan, United Arab Emirates, Uzbekistan, Vietnam Africa Algeria, Angola, Botswana, Côte d’Ivoire, Egypt, Ghana, Kenya, Libya, Madagascar, Mauritius, Morocco, Nigeria, Senegal, Seychelles, South Africa, Tunisia North America & Caribbean Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Panama, Trinidad and Tobago South America Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay, Venezuela This app and device are NOT FDA-cleared and are not intended for sale or use in the United States or in any other country or region not listed above. Disclaimer: Always consult your healthcare provider before making any treatment decisions. Do not use this app as a substitute for professional medical advice.